Immatics N.V.(IMTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IMTX Immatics N.V.

交易中 02-09 15:52:11 EST

10.14

+0.51

+5.30%

最高10.18	最低9.43	成交量38.54万
今开9.64	昨收9.63	日振幅7.84%
总市值13.59亿	流通市值6.34亿	总股本1.34亿
成交额380.71万	换手率0.62%	流通股本6,252万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IMTX","market":"US","secType":"STK","nameCN":"Immatics N.V.","latestPrice":10.14,"timestamp":1770670328889,"preClose":9.63,"halted":0,"volume":385355,"delay":0,"changeRate":0.05295950155763237,"floatShares":62524000,"shares":134063829,"eps":-1.1224,"marketStatus":"交易中","change":0.51,"latestTime":"02-09 15:52:11 EST","open":9.64,"high":10.18,"low":9.425,"amount":3807081.196615,"amplitude":0.078401,"askPrice":10.13,"askSize":11,"bidPrice":10.1,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.1224,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1770670800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":9.63,"postHourTrading":{"tag":"盘后","latestPrice":9.55,"preClose":9.63,"latestTime":"17:43 EST","volume":14315,"amount":137750.53,"timestamp":1770417786658,"change":-0.08,"changeRate":-0.008307,"amplitude":0.001038},"volumeRatio":1.018969,"impliedVol":1.0869,"impliedVolPercentile":0.8287},"requestUrl":"/m/hq/s/IMTX/tweets","defaultTab":"tweets","newsList":[{"id":"2592191286","title":"Immatics N.V.盘中异动 早盘快速上涨5.02%报10.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592191286","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592191286?lang=zh_cn&edition=full","pubTime":"2025-12-20 00:20","pubTimestamp":1766161245,"startTime":"0","endTime":"0","summary":"北京时间2025年12月20日00时20分，Immatics N.V.股票出现波动，股价大幅拉升5.02%。截至发稿，该股报10.05美元/股，成交量5.732万股，换手率0.04%，振幅4.81%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为1.45%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研发用于治疗癌症患者的T细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司签订战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220002045a6b7e1cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220002045a6b7e1cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2585489844","title":"Immatics N.V.2025财年第三财季实现净利润-59.06百万美元，同比减少527.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585489844","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585489844?lang=zh_cn&edition=full","pubTime":"2025-11-23 00:02","pubTimestamp":1763827328,"startTime":"0","endTime":"0","summary":"11月23日，Immatics N.V.公布财报，公告显示公司2025财年第三财季净利润为-59.06百万美元，同比减少527.63%；其中营业收入为6.06百万美元，同比减少89.09%，每股基本收益为-0.49美元。从资产负债表来看，Immatics N.V.总负债1.20亿美元，其中短期债务3.38百万美元，资产负债比为5.08，流动比率为0.08。该公司通过与第三方制药和生物技术公司签订战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251123000222a70b0755&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251123000222a70b0755&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX"],"gpt_icon":0},{"id":"2585119620","title":"Immatics N.V.盘中异动 股价大涨5.23%报10.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585119620","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585119620?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:48","pubTimestamp":1763650087,"startTime":"0","endTime":"0","summary":"北京时间2025年11月20日22时48分，Immatics N.V.股票出现异动，股价大幅上涨5.23%。截至发稿，该股报10.87美元/股，成交量6.373万股，换手率0.05%，振幅3.44%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为1.45%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研发用于治疗癌症患者的T细胞重定向免疫疗法。消息层面，截至22时48分，《Guggenheim维持Immatics买入评级，上调目标价至19美元》资讯为影响Immatics N.V.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511202248089510cdd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511202248089510cdd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"1114739798","title":"Immatics N.V.任命Venkat Ramanan为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1114739798","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114739798?lang=zh_cn&edition=full","pubTime":"2025-10-01 19:36","pubTimestamp":1759318603,"startTime":"0","endTime":"0","summary":"Immatics N.V.宣布任命Venkat Ramanan为公司首席财务官。\nVenkat Ramanan将接替Arnd Christ担任Immatics N.V.的首席财务官职务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2564368027","title":"Immatics N.V.盘中异动 早盘快速上涨5.70%报5.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564368027","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564368027?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:47","pubTimestamp":1756820875,"startTime":"0","endTime":"0","summary":"北京时间2025年09月02日21时47分，Immatics N.V.股票出现异动，股价大幅上涨5.70%。截至发稿，该股报5.38美元/股，成交量73.1074万股，换手率0.60%，振幅5.70%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为0.55%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，从事用于治疗癌症患者的 T 细胞重定向免疫疗法的研发。该公司通过与第三方制药和生物技术公司签订战略合作协议来赚取收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250902214755a4afdda5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250902214755a4afdda5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2559985879","title":"Immatics N.V.盘中异动 大幅下跌11.84%报5.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2559985879","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559985879?lang=zh_cn&edition=full","pubTime":"2025-08-13 21:34","pubTimestamp":1755092042,"startTime":"0","endTime":"0","summary":"北京时间2025年08月13日21时34分，Immatics N.V.股票出现波动，股价急速跳水11.84%。截至发稿，该股报5.66美元/股，成交量7.8953万股，换手率0.06%，振幅9.74%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为0.44%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，从事用于治疗癌症患者的 T 细胞重定向免疫疗法的研发。该公司通过与第三方制药和生物技术公司签订战略合作协议来赚取收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250813213402a486789b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250813213402a486789b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMTX"],"gpt_icon":0},{"id":"2557932306","title":"Immatics N.V.盘中异动 大幅下挫5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557932306","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557932306?lang=zh_cn&edition=full","pubTime":"2025-08-07 00:09","pubTimestamp":1754496587,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日00时09分，Immatics N.V.股票出现波动，股价大幅下挫5.26%。截至发稿，该股报6.30美元/股，成交量18.9971万股，换手率0.16%，振幅4.66%。Immatics N.V.股票所在的生物技术行业中，整体跌幅为0.08%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，从事用于治疗癌症患者的 T 细胞重定向免疫疗法的研发。该公司通过与第三方制药和生物技术公司签订战略合作协议来赚取收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807000947a6d6ee32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807000947a6d6ee32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2555834175","title":"Immatics N.V.盘中异动 快速跳水5.24%报6.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555834175","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555834175?lang=zh_cn&edition=full","pubTime":"2025-07-31 23:12","pubTimestamp":1753974740,"startTime":"0","endTime":"0","summary":"北京时间2025年07月31日23时12分，Immatics N.V.股票出现波动，股价急速下挫5.24%。截至发稿，该股报6.33美元/股，成交量19.5405万股，换手率0.16%，振幅5.94%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为2.54%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，从事用于治疗癌症患者的 T 细胞重定向免疫疗法的研发。该公司通过与第三方制药和生物技术公司签订战略合作协议来赚取收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731231220a46dda79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731231220a46dda79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2517496129","title":"Immatics N.V.盘中异动 快速上涨5.07%报4.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517496129","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517496129?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:35","pubTimestamp":1741188909,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日23时35分，Immatics N.V.股票出现异动，股价急速拉升5.07%。截至发稿，该股报4.56美元/股，成交量15.1305万股，换手率0.12%，振幅4.15%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为1.21%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305233510963aeccc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305233510963aeccc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2514049232","title":"Immatics N.V.盘中异动 临近收盘股价大跌5.27%报4.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514049232","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514049232?lang=zh_cn&edition=full","pubTime":"2025-02-26 04:54","pubTimestamp":1740516876,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日04时54分，Immatics N.V.股票出现异动，股价急速下跌5.27%。截至发稿，该股报4.41美元/股，成交量31.5867万股，换手率0.26%，振幅5.91%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为0.06%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226045436a253de03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226045436a253de03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2510803843","title":"Immatics N.V.盘中异动 早盘股价大跌5.41%报4.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510803843","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510803843?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:43","pubTimestamp":1739285034,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时43分，Immatics N.V.股票出现异动，股价大幅跳水5.41%。截至发稿，该股报4.99美元/股，成交量3.7235万股，换手率0.03%，振幅3.61%。Immatics N.V.股票所在的生物技术行业中，整体跌幅为1.36%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211224354abcb08fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211224354abcb08fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMTX"],"gpt_icon":0},{"id":"2509775354","title":"Immatics N.V.盘中异动 快速下跌5.04%报5.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509775354","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509775354?lang=zh_cn&edition=full","pubTime":"2025-02-08 04:01","pubTimestamp":1738958481,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日04时01分，Immatics N.V.股票出现波动，股价快速跳水5.04%。截至发稿，该股报5.37美元/股，成交量23.8529万股，换手率0.20%，振幅4.78%。Immatics N.V.股票所在的生物技术行业中，整体跌幅为0.66%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208040121961b6f8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208040121961b6f8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMTX"],"gpt_icon":0},{"id":"2509234140","title":"Immatics N.V.盘中异动 快速上涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509234140","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509234140?lang=zh_cn&edition=full","pubTime":"2025-02-06 01:31","pubTimestamp":1738776697,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日01时31分，Immatics N.V.股票出现异动，股价急速拉升5.07%。截至发稿，该股报5.70美元/股，成交量15.5771万股，换手率0.13%，振幅6.27%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为2.00%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206013137961926c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206013137961926c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2508272991","title":"Immatics N.V.盘中异动 下午盘急速下挫5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508272991","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508272991?lang=zh_cn&edition=full","pubTime":"2025-02-04 04:13","pubTimestamp":1738613586,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日04时13分，Immatics N.V.股票出现异动，股价大幅下跌5.03%。截至发稿，该股报5.20美元/股，成交量24.6576万股，换手率0.20%，振幅3.66%。Immatics N.V.股票所在的生物技术行业中，整体跌幅为0.29%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020404130698799d30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020404130698799d30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2504485299","title":"Immatics N.V.盘中异动 股价大跌5.04%报5.46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504485299","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504485299?lang=zh_cn&edition=full","pubTime":"2025-01-17 01:27","pubTimestamp":1737048434,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日01时27分，Immatics N.V.股票出现异动，股价快速下跌5.04%。截至发稿，该股报5.46美元/股，成交量26.5531万股，换手率0.22%，振幅5.48%。Immatics N.V.股票所在的生物技术行业中，整体跌幅为0.21%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117012714abad75de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117012714abad75de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2503640319","title":"Immatics N.V.盘中异动 大幅上涨5.86%报6.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503640319","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503640319?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:32","pubTimestamp":1736951553,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时32分，Immatics N.V.股票出现波动，股价快速上涨5.86%。截至发稿，该股报6.32美元/股，成交量1.1635万股，换手率0.01%，振幅3.18%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为0.77%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152232349604b426&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152232349604b426&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMTX"],"gpt_icon":0},{"id":"2503708584","title":"Immatics N.V.盘中异动 早盘快速下跌5.44%报6.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503708584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503708584?lang=zh_cn&edition=full","pubTime":"2025-01-14 00:01","pubTimestamp":1736784090,"startTime":"0","endTime":"0","summary":"北京时间2025年01月14日00时01分，Immatics N.V.股票出现异动，股价急速跳水5.44%。截至发稿，该股报6.08美元/股，成交量15.5791万股，换手率0.13%，振幅5.37%。Immatics N.V.股票所在的生物技术行业中，整体跌幅为0.95%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114000130aba94707&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114000130aba94707&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2502681356","title":"Immatics N.V.盘中异动 下午盘股价大跌5.02%报6.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502681356","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502681356?lang=zh_cn&edition=full","pubTime":"2025-01-11 02:15","pubTimestamp":1736532937,"startTime":"0","endTime":"0","summary":"北京时间2025年01月11日02时15分，Immatics N.V.股票出现异动，股价快速下挫5.02%。截至发稿，该股报6.62美元/股，成交量21.8234万股，换手率0.18%，振幅5.60%。Immatics N.V.股票所在的生物技术行业中，整体跌幅为1.94%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250111021537aba63414&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250111021537aba63414&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMTX"],"gpt_icon":0},{"id":"2500412957","title":"Immatics N.V.盘中异动 临近收盘股价大跌5.05%报7.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500412957","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500412957?lang=zh_cn&edition=full","pubTime":"2025-01-04 04:34","pubTimestamp":1735936450,"startTime":"0","endTime":"0","summary":"北京时间2025年01月04日04时34分，Immatics N.V.股票出现异动，股价快速下跌5.05%。截至发稿，该股报7.05美元/股，成交量42.4681万股，换手率0.35%，振幅5.93%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为0.63%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250104043410a214b039&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250104043410a214b039&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0},{"id":"2500292070","title":"Immatics N.V.盘中异动 快速拉升5.06%报7.47美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500292070","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500292070?lang=zh_cn&edition=full","pubTime":"2025-01-02 23:15","pubTimestamp":1735830910,"startTime":"0","endTime":"0","summary":"北京时间2025年01月02日23时15分，Immatics N.V.股票出现波动，股价急速上涨5.06%。截至发稿，该股报7.47美元/股，成交量8.7296万股，换手率0.07%，振幅5.63%。Immatics N.V.股票所在的生物技术行业中，整体涨幅为0.96%。Immatics N.V.公司简介：Immatics NV 是一家生物技术公司，致力于研究和开发用于治疗癌症患者的 T 细胞重定向免疫疗法。该公司通过与第三方制药和生物技术公司的战略合作协议获得收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102231510ab9c0175&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102231510ab9c0175&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMTX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immatics.com","stockEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":-0.0213},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.5583},{"period":"1year","weight":0.7044},{"period":"ytd","weight":-0.0829}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Immatics N.V.于2020年3月10日成立，是一家荷兰私人有限责任公司。该公司是一家专注于开发基于T细胞受体的免疫疗法的生物制药公司。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.095881},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.039559},{"month":3,"riseRate":0.4,"avgChangeRate":-0.055575},{"month":4,"riseRate":0.6,"avgChangeRate":0.030451},{"month":5,"riseRate":0.6,"avgChangeRate":0.084766},{"month":6,"riseRate":0.8,"avgChangeRate":0.090549},{"month":7,"riseRate":1,"avgChangeRate":0.118289},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.038414},{"month":9,"riseRate":0.5,"avgChangeRate":0.095752},{"month":10,"riseRate":0.5,"avgChangeRate":-0.022532},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.02935},{"month":12,"riseRate":0.5,"avgChangeRate":0.016402}],"exchange":"NASDAQ","name":"Immatics N.V.","nameEN":"Immatics N.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immatics N.V.(IMTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Immatics N.V.(IMTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Immatics N.V.,IMTX,Immatics N.V.股票,Immatics N.V.股票老虎,Immatics N.V.股票老虎国际,Immatics N.V.行情,Immatics N.V.股票行情,Immatics N.V.股价,Immatics N.V.股市,Immatics N.V.股票价格,Immatics N.V.股票交易,Immatics N.V.股票购买,Immatics N.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immatics N.V.(IMTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Immatics N.V.(IMTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}